Ocrelizumb

Indications & Dose:

Multiple sclerosis (specialist use only)

BY INTRAVENOUS INFUSION

Adult: Initially 300 mg, then 300 mg after 2 weeks maintenance 600 mg every 6 months, the first maintenance dose should be given 6 months after the first initial dose a minimum interval of 5 months should be maintained between each maintenance dose, for dose interruption, adjustment of infusion rate or discontinuation of treatment due to infusion-related reactions or side-effects—consult product literature

CONTRA-INDICATIONS Active infection . active malignancies . severely immunocompromised patients

Contraindications:

-

Side Effects:

Common or very common Catarrh

Frequency not known Malignancy

CONCEPTION AND CONTRACEPTION Manufacturer advises women of childbearing potential should use contraception during treatment and for 12 months after the last dose.

PREGNANCY Advises avoid unless potential benefit outweighs risk-limited information available monitor infants for B-cell depletion.

BREASTFEEDING Advises avoid&mdash present in milk in animal studies.

Cautions:

Complete required vaccinations at least 6 weeks before treatment initiation . hepatitis B reactivation

Precautions:

-

Interaction:

-

Warnings:

-

Adverse Effects:

-

Lactations:

-

Special Precautions:

-

Counselling:

-

Side Effects Or Adverse Reactions:

-

Patient And Carer Advice:

-